Please login to the form below

Not currently logged in
Email:
Password:

asthma drug

This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

News from pharma, biotech and healthcare. Limited NICE approval for AZ’s asthma drug Fasenra. ... However, the UK's cost-effectiveness watchdog says the drug should only be used in limited circumstances for eosinophilic asthma, when usual therapies

Latest news

  • PMCPA takes AZ to task over asthma drug press release PMCPA takes AZ to task over asthma drug press release

    PMCPA takes AZ to task over asthma drug press release. Concluded that the data in the release had not been “placed in context”. ... A complaint filed by GlaxoSmithKline against AstraZeneca about a press release for its severe asthma drug Fasenra,

  • Dermira craters as acne drug fails late-stage test Dermira craters as acne drug fails late-stage test

    Dermira craters as acne drug fails late-stage test. The US biotech lost two-thirds of its share value after the news broke. ... s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AZ gets EMA green light for severe asthma drug Fasenra. The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero. ... The new drug has been given a green light by the EMA as an add-on maintenance treatment for severe

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    AZ prices severe asthma drug Fasenra below competition. The discounted drug will cost $38, 000 in the first year. ... The US regulator has approved the drug as an add-on treatment for severe eosinophilic asthma in patients over 12.

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ severe asthma drug benralizumab backed by CHMP. The IL-5 inhibitor set for European approval to treat severe eosinophilic asthma. ... In trials, benralizumab achieved up to 51% reduction in the annual asthma exacerbations rate (AERR) versus placebo,

More from news
Approximately 2 fully matching, plus 119 partially matching documents found.

Latest Intelligence

  • US health reforms US health reforms

    In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by

  • Building BRICs: pharma's key emerging markets are becoming giants Building BRICs: pharma's key emerging markets are becoming giants

    In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Enterprise Therapeutics appoints CEO Enterprise Therapeutics appoints CEO

    Enterprise Therapeutics appoints CEO. Dr John Ford will lead the UK drug discovery company. ... He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002.

  • Former RBS head takes the reins as GSK chair Former RBS head takes the reins as GSK chair

    the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics